Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jamaneurol.2024.3825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gantenerumab in Dominantly Inherited Alzheimer Disease.
JAMA Neurol
November 2024
Research & Development, Chiesi Farmaceutici, Parma, Italy.
Gantenerumab in Dominantly Inherited Alzheimer Disease-Reply.
JAMA Neurol
November 2024
Department of Neurology, Washington University School of Medicine in St Louis Continuing Medical Education, St Louis, Missouri.
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement.
Alzheimers Dement
November 2024
Alzheimer's Association, Chicago, Illinois, USA.
The emergence of the United States Food and Drug Administration (FDA)-approved amyloid-targeting therapies for Alzheimer's disease challenges clinicians and healthcare providers with a transformative landscape. Effectively communicating the risks, benefits, burdens, costs, and available support associated with these novel disease-modifying treatments to patients, families, and other healthcare providers is essential but complex. In response, the Alzheimer's Association's Clinical Meaningfulness Workgroup has proposed language surrounding treatment eligibility, benefits, amyloid-related imaging abnormalities (ARIA), apolipoprotein E (APOE) genotyping, and treatment costs, serving as a resource to healthcare professionals in navigating discussions with patients and their families.
View Article and Find Full Text PDFAssociation of Resilience-Related Life Experiences on Variability on Age of Onset in Dominantly Inherited Alzheimer Disease.
Neurology
October 2024
From the Department of Nuclear Medicine (H.J.S., Jai-Hyuen Lee), Dankook University College of Medicine, Cheonan, Chung Nam; Department of Nuclear Medicine (J.S.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Neurology (R.J.B., J.J.L.-G., J.C.M., A.D.), Washington University School of Medicine, St. Louis, MO; Department of Clinical Epidemiology and Biostatistics (S.K.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea; Department of Neurology (G.S.D.), Mayo Clinic College of Medicine and Science, Jacksonville, FL; Department of Neurology (J.P.C.), Massachusetts General Hospital, Harvard Medical School, Boston; Department of Neurology (S.B.B.), University of Pittsburgh School of Medicine, PA; Neuroscience Research Australia (P.R.S.); School of Medical Sciences (P.R.S.), University of New South Wales, Sydney, Australia; Department of Cellular Neurology (M.J.), Hertie Institute for Clinical Brain Research, University of Tübingen; German Center for Neurodegenerative Diseases (M.J.), Tübingen; Department of Neurology (J.L.), Ludwig-Maximilians-Universität München; German Center for Neurodegenerative Diseases (J.L.), Munich; Munich Cluster for Systems Neurology (SyNergy) (J.L.), Germany; Department of Neurology (Jae-Hong Lee), University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea; Department of Pathology and Immunology (R.J.P.), Knight Alzheimer's Disease Research Center (R.J.P., J.H.), and Department of Neurology (R.J.P., J.H.), Washington University in St. Louis; Department of Psychiatry (C.C.), Washington University School of Medicine; Department of Psychological and Brain Sciences (J.H.), Washington University, St. Louis, MO; and Department of Neurology (S.P.S.), The Warren Alpert Medical School of Brown University, Butler Hospital, Providence, RI.
Article Synopsis
- The study examines the link between protective lifestyle factors and the age at symptom onset of autosomal dominant Alzheimer disease (ADAD), which is largely influenced by genetics, focusing on how resilience-related experiences may impact this relationship.
- The researchers analyzed data from the Dominantly Inherited Alzheimer Network, assessing both clinical and lifestyle factors in two groups: one looking at general resilience among people showing cognitive stability despite high pathology and another focusing on specific genetic timelines for ADAD.
- Findings from 320 participants indicate variations in age at onset among carriers based on lifestyle and resilience factors, revealing potential avenues for understanding how these influences might delay the onset of symptoms in genetically predisposed individuals.
Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials.
J Prev Alzheimers Dis
May 2024
Jorge J Llibre Guerra, 4488 Forest Park 00328, T: 314.273-5439, St. Louis MO 63108, USA, Haiyan Liu, 4488 Forest Park 00328, T: 314.273-5819, St. Louis MO 63108, USA,
Background: Clinical trial satisfaction is increasingly important for future trial designs and is associated with treatment adherence and willingness to enroll in future research studies or to recommend trial participation. In this post-trial survey, we examined participant satisfaction and attitudes toward future clinical trials in the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU).
Methods: We developed an anonymous, participant satisfaction survey tailored to participants enrolled in the DIAN-TU-001 double-blind clinical trial of solanezumab or gantenerumab and requested that all study sites share the survey with their trial participants.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!